- Home
- GERN vs RLX Comparison
GERN vs RLX Comparison
Compare GERN & RLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GERN | RLX |
|---|---|---|
| Founded | 1990 | 2018 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 2.2B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GERN | RLX |
|---|---|---|
| Price | $1.31 | $1.75 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 1 |
| Target Price | $2.17 | ★ $2.50 |
| AVG Volume (30 Days) | ★ 8.8M | 3.2M |
| Earning Date | 05-06-2026 | 05-15-2026 |
| Dividend Yield | N/A | ★ 0.75% |
| EPS Growth | ★ 51.85 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,065,000.00 | N/A |
| Revenue This Year | $26.91 | $55.89 |
| Revenue Next Year | $43.75 | $15.07 |
| P/E Ratio | ★ N/A | $28.09 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.04 | $1.67 |
| 52 Week High | $2.01 | $2.68 |
Technical Indicators
Market Signals| Indicator | GERN | RLX |
|---|---|---|
| Relative Strength Index (RSI) | 39.30 | 40.91 |
| Support Level | $1.24 | N/A |
| Resistance Level | $1.32 | $1.85 |
| Average True Range (ATR) | 0.07 | 0.05 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 10.00 | 44.00 |
Price Performance
Historical ComparisonAbout GERN Geron Corporation
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
About RLX RLX Technology Inc. each representing the right to receive one (1) ordinary share
RLX Technology Inc is engaged in the manufacturing of e-vapor products for adult smokers. It has an integrated offline distribution and "Branded store plus" retail model tailored to China's e-vapor market. The company has two reportable segments, Core Markets and Europe Acquisition. The majority of the revenue is earn from Core Markets segment.